粪便免疫化学试验筛查大肠癌的研究进展  

A review of clinical research on using FIT screening for colorectal cancer

作　　者：曾凡 陈晨 黄士美 张大涯 白飞虎 ZENG Fan;CHEN Chen;HUANG Shi-mei;ZHANG Da-ya;BAI Fei-hu(Hainan Medical University,Haikou 571199,China;The Second Affiliated Hospital of Hainan Medical University,Haikou 570216,China;The Gastroenterology Clinical Medical Center of Hainan Province,Haikou 570216,China)

机构地区：[1]海南医学院,海南海口571199 [2]海南医学院第二附属医院,海南海口570216 [3]海南省消化疾病临床研究中心,海南海口570216

出　　处：《海南医学院学报》2023年第22期1748-1754,共7页Journal of Hainan Medical University

基　　金：海南省临床医学中心建设项目资助(2021818);海南省院士团队创新中心建设项目资助(2022136);海南省院士创新平台科研项目资金资助(00817378);海南省卫生健康行业科研项目资助(22A200078);海南省研究生创新科研课题(Qhyb2022-133)。

摘　　要：大肠癌已经成为全世界第三大常见癌症,癌症相关的第二大死因。早期筛查可降低CRC的发生率和死亡率。随着粪便免疫化学试验的发展,FIT已经成为全世界大肠癌高危人群筛查大肠癌的重要手段。本文就FIT筛查CRC的研究进展进行阐述。Colorectal cancer has become the third most common cancer in the world and the second leading cause of death related to cancer.Early screening of CRC can reduce its incidence rate and mortality.With the development of fecal immunochemi-cal test,FIT has been an important tool for screening CRC patients in high-risk groups worldwide.In this paper,we describe the research progress of FIT screening for CRC.

关 键 词：大肠癌 粪便免疫化学检测 筛查 

分 类 号：R735.34[医药卫生—肿瘤]